Ketamine and Classic Psychedelics Are Not the Same

Ketamine often appears in the same conversations as psilocybin, LSD and MDMA. That grouping can be useful when discussing altered states or novel mental-health treatments—but pharmacologically, clinically and legally, ketamine is different.

Clear categories matter because the evidence, risks and access routes are not interchangeable. A finding about ketamine cannot be transferred to classic psychedelics, and language about “psychedelic therapy” can hide important differences between products and care models.

How ketamine differs pharmacologically

Ketamine is primarily an N-methyl-D-aspartate receptor antagonist. It produces dissociation, analgesia and anaesthesia, with effects that vary by dose and route. Its rapid antidepressant actions are thought to involve downstream glutamate signalling and synaptic plasticity, though mechanisms remain under investigation.

Classic psychedelics such as psilocin and LSD act principally as serotonin 2A receptor agonists. They can alter perception and meaning in overlapping ways, but shared subjective features do not make the compounds equivalent.

Medical use and off-label depression care

Ketamine has long-established licensed uses in anaesthesia. In mental-health settings, some specialist services administer ketamine off-label for severe depression after clinical assessment and with monitoring. Off-label means a licensed medicine is being used outside the exact terms of its marketing authorisation.

Esketamine is one mirror-image form of the ketamine molecule and is marketed as a nasal product for depression in some countries. Product approval, commissioning and clinical availability are jurisdiction-specific. They should not be described as universal access.

What depression evidence shows

Research has repeatedly found that ketamine can reduce depressive symptoms rapidly for some people, including after other treatments have not helped. Benefits may emerge within hours or days, which differs from the time course of many conventional antidepressants.

Rapid onset does not guarantee durable recovery. Some people relapse after treatment stops, and repeated or maintenance dosing raises questions about long-term safety, dependence, service burden and who should continue. Clinical decisions need to balance short-term response against these uncertainties.

Esketamine and NICE

NICE’s technology appraisal does not recommend esketamine nasal spray with a conventional antidepressant for treatment-resistant depression in the NHS in England. The appraisal concluded that uncertainties in clinical evidence and cost-effectiveness were too substantial for routine recommendation.

NICE’s exceptional surveillance review in 2026 did not change that position. This illustrates a recurring distinction: a product may have a marketing authorisation while a health system decides that evidence and value do not support routine funding.

Risks and monitoring

Acute effects can include dissociation, sedation, increased blood pressure, nausea, anxiety, perceptual disturbance and impaired coordination or judgement. Clinical services monitor patients and place restrictions around leaving, driving and decision-making after treatment.

Repeated or heavy non-medical use is associated with dependence, cognitive concerns and serious urinary-tract harm, including ketamine-induced uropathy. The UK Advisory Council on the Misuse of Drugs’ 2026 review emphasised the changing scale of use and harms. Clinical exposure and uncontrolled use are different, but both inform responsible risk communication.

Psychological support models are not interchangeable

Some clinics provide ketamine primarily as a pharmacological antidepressant with medical monitoring. Others combine it with structured psychotherapy. Research questions and outcome attribution differ between these models.

The term “ketamine-assisted psychotherapy” should therefore be tied to a clearly described protocol. Evidence for intravenous ketamine in a monitored service cannot automatically validate a different route, dose, therapist model or commercial package.

UK law and access

Ketamine is a Class B, Schedule 2 controlled drug in the UK. Schedule 2 status permits recognised medical use within controlled-drug rules, unlike Schedule 1 status, which applies to substances including LSD and psilocin.

That distinction explains why lawful ketamine prescribing and licensed possession can exist while psilocybin research generally requires a different licensing route. It does not mean ketamine is low-risk or appropriate for a particular person.

How to compare claims responsibly

When an article uses the phrase “psychedelic treatment”, identify the exact substance, formulation, route, dose, indication, support model and follow-up. Ask whether the evidence concerns a licensed use, off-label practice, an investigational product or non-medical use.

Broad category language can be helpful at the beginning of a discussion. It should never replace the details needed to judge benefit, risk or legality.

Sources and further reading

• British National Formulary: Ketamine — UK clinical reference for indications, cautions and adverse effects
• NICE TA854: Esketamine nasal spray — NHS England technology-appraisal recommendation
• Oxford Health NHS ketamine service information (2026) — specialist-service description and patient safety information
• ACMD: Ketamine—updated review of use and harms (2026) — UK evidence review of population-level use and harms
• UK controlled-drugs list — current classification and scheduling